From: The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive
Non-recurrent positive | Recurrent positive | P value | |
---|---|---|---|
No. of patients | 170 | 241 | |
Sex | |||
Female | 81 (47.65%) | 121 (50.21%) | 0.609 |
Male | 89 (52.35%) | 120 (49.79%) | |
Age, Median (IQR), year | 47.00 (35.00–61.00) | 50.00 (38.00–63.00) | 0.023 |
BMI, Mean (SD), kg/m2 | 22.93 (3.24) | 22.98 (4.35) | 0.894 |
SPD, Median (IQR), day | 16.50 (12.00–24.00) | 20.00 (13.00–29.00) | 0.020 |
Routine blood test | |||
WBC, Mean (SD), × 109/L | 5.37 (1.89) | 6.22 (2.69) | < 0.001 |
NC, Median (IQR), × 109/L | 2.86 (2.15–3.91) | 3.10 (2.36–4.18) | 0.163 |
NP, Mean (SD), % | 58.69 (12.60) | 54.90 (17.74) | 0.017 |
LC, Median (IQR), × 109/L | 1.34 (1.00–1.80) | 1.63 (1.24–2.12) | < 0.001 |
LP, Mean (SD), % | 29.73 (11.86) | 31.71 (14.66) | 0.146 |
MC, Median (IQR), × 109/L | 0.49 (0.39–0.63) | 0.43 (0.34–0.56) | 0.005 |
MP, Median (IQR), % | 9.75 (7.53–12.50) | 7.40 (6.10–9.40) | < 0.001 |
Hemoglobin, Mean (SD), g/L | 130.98 (16.20) | 128.03 (21.38) | 0.130 |
PLT, Mean (SD), × 109/L | 203.06 (66.38) | 219.19 (74.74) | 0.025 |
Clinical type | |||
Mild | 7 (4.12%) | 22 (9.13%) | 0.141 |
Moderate | 141 (82.94%) | 179 (74.27%) | |
Severe | 17 (10.00%) | 32 (13.28%) | |
Critical | 5 (2.94%) | 8 (3.32%) | |
Underlying disease | |||
No. of chronic diseases | |||
0 | 123 (72.35%) | 139 (57.68%) | 0.002 |
1 | 35 (20.59%) | 65 (26.97%) | |
2 | 12 (7.06%) | 21 (8.71%) | |
3 | 0 (0.00%) | 12 (4.98%) | |
4 | 0 (0.00%) | 4 (1.66%) | |
Hypertension | |||
No | 144 (84.71%) | 191 (79.25%) | 0.161 |
Yes | 26 (15.29%) | 50 (20.75%) | |
Diabetes | |||
No | 157 (92.35%) | 218 (90.46%) | 0.503 |
Yes | 13 (7.65%) | 23 (9.54%) | |
CHD | |||
No | 166 (97.65%) | 227 (94.19%) | 0.092 |
Yes | 4 (2.35%) | 14 (5.81%) | |
CPD | |||
No | 165 (97.06%) | 225 (93.36%) | 0.094 |
Yes | 5 (2.94%) | 16 (6.64%) | |
CKD | |||
No | 168 (98.82%) | 238 (98.76%) | 0.95 |
Yes | 2 (1.18%) | 3 (1.24%) | |
CLD | |||
No | 162 (95.29%) | 203 (84.23%) | < 0.001 |
Yes | 8 (4.71%) | 38 (15.77%) | |
Malignant tumor | |||
No | 168 (98.82%) | 236 (97.93%) | 0.705 |
Yes | 2 (1.18%) | 5 (2.07%) | |
Treatment | |||
No. of antiviral drugs | |||
0 | 32 (18.82%) | 46 (19.09%) | 0.001 |
1 | 72 (42.35%) | 106 (43.98%) | |
2 | 47 (27.65%) | 84 (34.85%) | |
3 | 19 (11.18%) | 5 (2.07%) | |
Glucocorticoid | |||
No | 143 (84.12%) | 223 (92.53%) | 0.007 |
Yes | 27 (15.88%) | 18 (7.47%) |